Real-World Studies
Patient Treatment Preferences in Waldenström Macroglobulinemia
Becking et alBlood Neoplasia
In Waldenström macroglobulinemia (WM), therapeutic options lack a uniform standard approach, presenting distinct differences across efficacy, administration routes, and safety profiles. The international WM-VOICE study quantified patient treatment preferences using a web-based discrete choice experiment (DCE) administered across five high-income countries. The study evaluated 1,455 participants—of whom 75% were aged 61 to 80 years, 56% were male, and 79% had received prior therapy.
The DCE utilized 16 choice sets in which patients selected between two hypothetical therapy profiles defined by six attributes: response duration (2, 4, 6, or 8 years), mode of administration (hospital infusions vs pills at home), treatment duration (6 months, 2 years, or ongoing), temporary toxicities (grade 0–1, 2, or 3–4), persistent toxicities (grade 0–1 or 2), and secondary malignancy risk (increased vs not increased). Repeated choice data were evaluated via a panel mixed logit model.
All evaluated attributes significantly influenced patient choices, demonstrating consistent preference patterns across all five included countries. Response duration and temporary toxicity were identified as the primary drivers of therapy choice, followed by the risk of secondary malignancies and persistent toxicities. In contrast, administration route and treatment duration had a comparatively smaller impact on patient selections, despite an observed baseline preference for oral, fixed-duration regimens over ongoing or intravenous approaches.
These findings indicate that patients with WM place the greatest value on achieving durable remissions while avoiding severe adverse events, prioritizing these factors over logistical considerations like administration route and regimen duration. These preference data provide actionable insights to guide shared decision-making discussions in clinical practice and assist investigators in designing patient-centered clinical trials and development programs.
Key Takeaways
- In an international discrete choice experiment of 1,455 patients with Waldenström macroglobulinemia, response duration and temporary toxicity emerged as the two most influential determinants driving therapy selection, followed by secondary malignancy risk and persistent toxicity.
- Although patients demonstrated a preference for oral administration and fixed-duration treatment, administration mode and treatment duration exerted relatively less influence on decision-making compared to efficacy and adverse-effect profiles.
Read the original sourceBlood Neoplasia
